Comparative Pharmacology
Head-to-head clinical analysis: SULFISOXAZOLE DIOLAMINE versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFISOXAZOLE DIOLAMINE versus SULSOXIN.
SULFISOXAZOLE DIOLAMINE vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole diolamine is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
2-4 g orally initially, followed by 4-8 g/day in 4-6 divided doses for urinary tract infections; 6-8 g/day in 4-6 divided doses for nocardiosis.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
5-10 hours (prolonged in renal impairment; normal half-life in adults ~6 hours)
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal: 70-100% (primarily as unchanged drug and acetylated metabolite); Biliary/Fecal: <5%
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic